Skip to main content

Wistuba II

First name:
Wistuba
Suffix:
II
Reuben, A. ., Spencer, C. ., Prieto, P. ., , Reddy, S. ., Miller, J. ., … Wargo, J. . Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genomic Medicine, 2. https://doi.org/10.1038/s41525-017-0013-8 (Original work published 2017)
Reuben, A. ., Gittelman, R. ., Gao, J. ., Zhang, J. ., Yusko, E. ., Wu, C. ., … Zhang, J. . (2017). TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 7(10), 1088-1097. https://doi.org/10.1158/2159-8290.CD-17-0256
Gao, J. ., Ward, J. ., Pettaway, C. ., Shi, L. ., Subudhi, S. ., Vence, L. ., … Sharma, P. . (2017). VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 23(5), 551-555. https://doi.org/10.1038/nm.4308